Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: A systematic review and meta-analysis

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2157-2166

  Yao, Yanhong ^a,b,c   Wang, Haitao ^a,b,c   Li, Baoguo ^a,b,c   Tang, Yong ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Research Group of Evidence based Clinical Oncology   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Detection; Meta analysis; Prostate cancer; Systematic review; TMPRSS2:ERG fusion gene

Indexed keywords

ARTICLE; BODY FLUID; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; META ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TMPRSS2 ERG GENE;

HUMANS; MALE; ODDS RATIO; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899108674     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1286-x     Document Type: Article

References (57)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-92.
3. Chun FK, Epstein JI, Ficarra V, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol. 2010;58(6):851-64.
4. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
5. Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484-9.
6. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644- 8.
7. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275-86.
8. Paulo P, Barros-Silva JD, Ribeiro FR, et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Gene Chromosome Cancer. 2012;51(3):240-9.
9. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15(14):4706-11.
10. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-41.
11. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12(7):590-8.
12. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012;136(8):935-46.
13. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089-95.
14. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res. 2010;16:1572-6.
15. Bories PN, Younes P, Zerbib M, Denjean L, Popovici T, et al. TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer. Clin Chem. 2013;59:245-51.
16. Dai MJ, Kong FH, Shen M, Zhou W, Chen W, et al. Quantitative detection of PCA3 mRNA and T1E4 mRNA - the isoform of fusion gene TMPRSS2: ERG in urine of patients for the early clinical diagnosis of prostate cancer. J Med Res. 2011;40:20-4.
17. Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res. 2013;33:191-7.
18. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem. 2013;59:280-8.
19. Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, et al. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem. 2008;54:2007-17.
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
21. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.
22. Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.
23. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med. 1998;122:675-86.
24. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882-93.
25. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
26. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002;21:1525-37.
27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
28. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2013;31(5):566-71.
29. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012. doi: 10.1016/j.eururo.2012.11.014.
30. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13:5103-8.
31. Robert G, Jannink S, Smit F, Aalders T, Hessels D, et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013;73:113-20.
32. Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, et al. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol. 2011;59:407-14.
33. Chan SW, Nguyen PN, Violette P, et al. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2: ETS fusion gene markers. Cancer Med. 2013;2(1):63-75.
34. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645-9.
35. Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int. 2011;61:409-14.
36. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24:1128-38.
37. Yaskiv O, Zhang X, Simmerman K, Daly T, He H, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35:1062-8.
38. Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, et al. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010;19:151-6.
39. Sun QP, Li LY, Chen Z, Pang J, Yang WJ, et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diagn. 2010;12:718-24.
40. Rouzier C, Haudebourg J, Carpentier X, Valerio L, Amiel J, et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet. 2008;183:21-7.
41. Yi FX, Li H, Wei Q, Li X, Zeng H. The Detection of TMPRSS2:ERG Fusion in Chinese with Prostate Cancer. J Clin Urol. 2011;26:215-7.
42. Xiang H, Ling ZX, Sun K, Ren GP, You QH, et al. Detection and significance of fusion gene between TMPRSS2 and ETS transcription factor genes in fresh prostatic cancer tissues in Chinese patients. Chin J Pathol. 2011;40:187-8.
43. Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Natl Med J China. 2008;88:669-73.
44. Sun QP, Pang J, Li LY, Zhou XF, Qiu JG, et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the diagnosis of prostate cancer. Chin J Endourol. 2010;4:64-8. Electronic Edition.
45. Mao YJ, He JJ, Xv G, Dai ML, Chen W, et al. The value of the ratio of transmembrane protease serine 2 and ETS-related gene fusion transcripts in the diagnosis of prostate cancer. Chin J Lab Med. 2009;32:905-9.
46. Ding XF, Zhou GC, Li HZ. Transmembrane protease serine 2-erythroblast transformation specific fusion gene tested by flurescence in situ hybridization in the early stage of prostate cancer. Chin J Exp Surg. 2012;29:2373-5.
47. Sun WG, Ai YK, Jiang LM. The expressions of TMPRSS2-ERG and P504s in prostate cacinoma using tissue chip and its clinical significance. Chin J Androl. 2012;26:8-12.
48. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21:67-75.
49. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-8.
50. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-93.
51. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826-32.
52. Ruiz-Aragon J, Marquez-Pelaez S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis. Actas Urol Esp. 2010;34(4):346-55.
53. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-35.
54. Mao X, Yu Y, Boyd LK, Ren G, Lin D, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70:5207-12.
55. Furusato B, Tan SH, Young D, Dobi A, Sun C, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-37.
56. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69(4):1400-6.
57. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.